Mutant cholera holotoxin as an adjuvant
US7384640B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 30, 1999 |
| Grant date | Jun 10, 2008 |
| Priority date | — |
| Expiry date | Sep 30, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18534
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus or parasite. In a particular embodiment, the amino acid 29 is histidine. The mutant cholera holotoxin may contain at least one additional mutation in the A subunit at a position other than amino acid 29. The antigenic composition may include a second adjuvant in addition to the mutant cholera holotoxin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.